Cannabis And Metabolic Syndrome: A New Piece In The Puzzle, A 'Leap In Understanding' (CORRECTED)

Editor's Note: This article has been corrected to properly attribute the information to Dr. Benjamin Caplan, rather than a study that appeared in the American Journal of Medicine. Benzinga takes full responsibility for the error and apologizes to Dr. Caplan and our readers.

A recent study published in the American Journal of Medicine Open reveals that cannabis could offer a new approach to treating metabolic disorders in young adults. According to Dr. Benjamin Caplan, who broadly analyzes the study in his Substack, the results present some surprising findings that could broaden our understanding of metabolic health.

Metabolic syndrome (MetS), is a combination of health issues, including high blood pressure, high blood sugar, abdominal obesity and abnormal cholesterol levels. This cluster of conditions increases the risk of heart disease, stroke and type 2 diabetes. According to the National Heart, Lung and Blood Institute, about 1 in 3 adults present this symptoms in the U.S.

Obesity: Can Marijuana Help?

Obesity has become a global health crisis, affecting people of all ages. In the United States, obesity rates among children and adolescents have tripled over the past three decades, and one in five school-aged children is now classified as obese. 

“In the midst of this growing epidemic of obesity and metabolic syndrome, it is more important than ever to find effective treatments and management strategies. Traditional approaches, which include lifestyle modifications and pharmacological interventions, have had some success, but they are not universally accessible and certainly don’t work for everyone,” says Caplan.

“The latest craze sweeping the world is the use of GLP-1 inhibitors (Ozempic, Wegovy, Monjaro, Victoza, Saxenda, Rybelsus, etc.), where the promise of weight loss, at least, seems ‘accessible’, although expensive, and the jury is still out on any long-term impacts,” he noted.

However, new research suggests that cannabis may offer a breakthrough solution for managing metabolic syndrome. The study, "Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity" analyzed data from the 2009-2018 National Health and Nutrition Surveys.

Why It Matters: A ‘Leap In Understanding‘

Results showed that cannabis users have a 42% lower prevalence of metabolic syndrome compared to non-users, with even more significant reductions for non-Hispanic Black individuals, who showed a 78% lower prevalence.

“This study represents a leap in understanding just how meaningfully cannabis might influence metabolic health,” Caplan said. “These staggering results highlight the amazing potential of cannabis to positively impact metabolic health, especially in populations that are disproportionately affected by metabolic syndrome.”

Broader Implications And Potential Benefits

“The relevance of the study reaches beyond the 18- to 25-year-old population. For people with limited access to traditional healthcare, cannabis could offer a more accessible and enjoyable way to manage metabolic health,” noted Caplan who adds that the potential of cannabis as a complementary therapy “is significant, especially given its interaction with the endocannabinoid system, which regulates metabolism, appetite and inflammation.”

Study's Scope And Constraints

“While the study's findings are promising, it's crucial to recognize its limitations,” Caplan pointed out. “Science demands a balanced perspective, evaluating reported benefits and concerns in the context of the specific population studied.”

In addition, he said, the research lacks detailed information on cannabis consumption habits such as strains, THC and CBD content and methods of consumption, which could influence the results.

That said, Caplan said medical benefits should be taken seriously.

“Policies must be informed by a nuanced understanding of cannabis's benefits and risks. As legalization approaches and acceptance of cannabis continue to grow, ensuring safe and informed use is paramount,” Caplan wrote. “This study adds a valuable piece to the puzzle but underscores the need for continued research and dialogue among healthcare providers, policymakers, and the public.”

Read Dr. Caplan´s full report here.

Cover image made with AI